CA3093386A1 - Constructions d'administration derivees de toxines pour administration orale - Google Patents
Constructions d'administration derivees de toxines pour administration orale Download PDFInfo
- Publication number
- CA3093386A1 CA3093386A1 CA3093386A CA3093386A CA3093386A1 CA 3093386 A1 CA3093386 A1 CA 3093386A1 CA 3093386 A CA3093386 A CA 3093386A CA 3093386 A CA3093386 A CA 3093386A CA 3093386 A1 CA3093386 A1 CA 3093386A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- delivery construct
- carrier
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 556
- 239000003053 toxin Substances 0.000 title description 14
- 231100000765 toxin Toxicity 0.000 title description 14
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 319
- 230000031998 transcytosis Effects 0.000 claims abstract description 101
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 691
- 125000000539 amino acid group Chemical group 0.000 claims description 334
- 239000012634 fragment Substances 0.000 claims description 251
- 238000000034 method Methods 0.000 claims description 246
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 203
- 239000002095 exotoxin Substances 0.000 claims description 201
- 231100000776 exotoxin Toxicity 0.000 claims description 201
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 199
- 125000006850 spacer group Chemical group 0.000 claims description 194
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 167
- 229920001184 polypeptide Polymers 0.000 claims description 161
- 210000004027 cell Anatomy 0.000 claims description 114
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims description 87
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 230000003993 interaction Effects 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 45
- 150000007523 nucleic acids Chemical class 0.000 claims description 45
- -1 TIViEM132 Proteins 0.000 claims description 43
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 238000001727 in vivo Methods 0.000 claims description 42
- 102000040430 polynucleotide Human genes 0.000 claims description 40
- 108091033319 polynucleotide Proteins 0.000 claims description 40
- 239000002157 polynucleotide Substances 0.000 claims description 40
- 108010017007 glucose-regulated proteins Proteins 0.000 claims description 37
- 230000012202 endocytosis Effects 0.000 claims description 35
- 101001038300 Homo sapiens Protein ERGIC-53 Proteins 0.000 claims description 32
- 102100040252 Protein ERGIC-53 Human genes 0.000 claims description 32
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 claims description 31
- 238000012217 deletion Methods 0.000 claims description 30
- 230000037430 deletion Effects 0.000 claims description 30
- 108010049224 perlecan Proteins 0.000 claims description 30
- 230000035772 mutation Effects 0.000 claims description 28
- 230000003834 intracellular effect Effects 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 238000000338 in vitro Methods 0.000 claims description 25
- 108020004414 DNA Proteins 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 108010054624 red fluorescent protein Proteins 0.000 claims description 24
- 150000003384 small molecules Chemical group 0.000 claims description 23
- 101150015999 sec24 gene Proteins 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 21
- 101710200247 Cholix toxin Proteins 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 241000283984 Rodentia Species 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 108091023037 Aptamer Proteins 0.000 claims description 13
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 13
- 238000011321 prophylaxis Methods 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000000710 homodimer Substances 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 208000030159 metabolic disease Diseases 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 102100030703 Interleukin-22 Human genes 0.000 claims description 8
- 239000002872 contrast media Substances 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 239000002356 single layer Substances 0.000 claims description 8
- 238000006471 dimerization reaction Methods 0.000 claims description 7
- 229920002521 macromolecule Polymers 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 102000005853 Clathrin Human genes 0.000 claims description 6
- 108010019874 Clathrin Proteins 0.000 claims description 6
- 206010056438 Growth hormone deficiency Diseases 0.000 claims description 6
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 208000026928 Turner syndrome Diseases 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 229930193282 clathrin Natural products 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 239000004055 small Interfering RNA Substances 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 5
- 102100033859 G-protein coupled receptor 78 Human genes 0.000 claims description 5
- 208000003807 Graves Disease Diseases 0.000 claims description 5
- 208000015023 Graves' disease Diseases 0.000 claims description 5
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 5
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 101001069603 Homo sapiens G-protein coupled receptor 78 Proteins 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 201000011152 Pemphigus Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 5
- 239000011149 active material Substances 0.000 claims description 5
- 201000005008 bacterial sepsis Diseases 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 210000003679 cervix uteri Anatomy 0.000 claims description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 5
- 201000001981 dermatomyositis Diseases 0.000 claims description 5
- 208000010706 fatty liver disease Diseases 0.000 claims description 5
- 208000037824 growth disorder Diseases 0.000 claims description 5
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 5
- 208000007475 hemolytic anemia Diseases 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 5
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 108091070501 miRNA Proteins 0.000 claims description 5
- 239000002679 microRNA Substances 0.000 claims description 5
- 206010028417 myasthenia gravis Diseases 0.000 claims description 5
- 210000001989 nasopharynx Anatomy 0.000 claims description 5
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 5
- 208000005987 polymyositis Diseases 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 229960004641 rituximab Drugs 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 claims description 4
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 claims description 4
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 claims description 4
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 108090000177 Interleukin-11 Proteins 0.000 claims description 4
- 102000003815 Interleukin-11 Human genes 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 102000013462 Interleukin-12 Human genes 0.000 claims description 4
- 108090000176 Interleukin-13 Proteins 0.000 claims description 4
- 108090000172 Interleukin-15 Proteins 0.000 claims description 4
- 102000003812 Interleukin-15 Human genes 0.000 claims description 4
- 101800003050 Interleukin-16 Proteins 0.000 claims description 4
- 108050003558 Interleukin-17 Proteins 0.000 claims description 4
- 102000013691 Interleukin-17 Human genes 0.000 claims description 4
- 108090000171 Interleukin-18 Proteins 0.000 claims description 4
- 108050009288 Interleukin-19 Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 108010065637 Interleukin-23 Proteins 0.000 claims description 4
- 102100036679 Interleukin-26 Human genes 0.000 claims description 4
- 108010066979 Interleukin-27 Proteins 0.000 claims description 4
- 108010002386 Interleukin-3 Proteins 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 102000004890 Interleukin-8 Human genes 0.000 claims description 4
- 108010002335 Interleukin-9 Proteins 0.000 claims description 4
- 229960002964 adalimumab Drugs 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 229960000598 infliximab Drugs 0.000 claims description 4
- 108090000681 interleukin 20 Proteins 0.000 claims description 4
- 108010074108 interleukin-21 Proteins 0.000 claims description 4
- 108010074109 interleukin-22 Proteins 0.000 claims description 4
- 108090000237 interleukin-24 Proteins 0.000 claims description 4
- 230000009834 selective interaction Effects 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 4
- 208000027496 Behcet disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 206010009895 Colitis ischaemic Diseases 0.000 claims description 3
- 206010056979 Colitis microscopic Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010053759 Growth retardation Diseases 0.000 claims description 3
- 206010029748 Noonan syndrome Diseases 0.000 claims description 3
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 3
- 102000048489 Short Stature Homeobox Human genes 0.000 claims description 3
- 108700025071 Short Stature Homeobox Proteins 0.000 claims description 3
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000008609 collagenous colitis Diseases 0.000 claims description 3
- 201000008243 diversion colitis Diseases 0.000 claims description 3
- 208000027138 indeterminate colitis Diseases 0.000 claims description 3
- 201000008222 ischemic colitis Diseases 0.000 claims description 3
- 208000004341 lymphocytic colitis Diseases 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 102100022760 Stress-70 protein, mitochondrial Human genes 0.000 claims 10
- 102100038803 Somatotropin Human genes 0.000 claims 1
- 230000032258 transport Effects 0.000 abstract description 107
- 230000003197 catalytic effect Effects 0.000 abstract description 24
- 230000005945 translocation Effects 0.000 abstract description 22
- 231100000699 Bacterial toxin Toxicity 0.000 abstract description 18
- 239000000688 bacterial toxin Substances 0.000 abstract description 18
- 231100000433 cytotoxic Toxicity 0.000 abstract description 4
- 230000001472 cytotoxic effect Effects 0.000 abstract description 4
- 235000001014 amino acid Nutrition 0.000 description 113
- 229940024606 amino acid Drugs 0.000 description 100
- 102000005962 receptors Human genes 0.000 description 98
- 108020003175 receptors Proteins 0.000 description 98
- 150000001413 amino acids Chemical class 0.000 description 93
- 238000002347 injection Methods 0.000 description 70
- 239000007924 injection Substances 0.000 description 70
- 230000027455 binding Effects 0.000 description 65
- 241000700159 Rattus Species 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 50
- 238000001514 detection method Methods 0.000 description 38
- 210000001035 gastrointestinal tract Anatomy 0.000 description 38
- 230000001580 bacterial effect Effects 0.000 description 35
- 239000000969 carrier Substances 0.000 description 34
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- 229940088598 enzyme Drugs 0.000 description 31
- 210000004400 mucous membrane Anatomy 0.000 description 30
- 231100000252 nontoxic Toxicity 0.000 description 30
- 230000003000 nontoxic effect Effects 0.000 description 30
- 239000000854 Human Growth Hormone Substances 0.000 description 27
- 238000006467 substitution reaction Methods 0.000 description 27
- 210000004379 membrane Anatomy 0.000 description 26
- 239000012528 membrane Substances 0.000 description 26
- 210000000981 epithelium Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 24
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 23
- 230000006870 function Effects 0.000 description 23
- 210000001630 jejunum Anatomy 0.000 description 22
- 102000002265 Human Growth Hormone Human genes 0.000 description 21
- 108010000521 Human Growth Hormone Proteins 0.000 description 21
- 108010070511 Keratin-8 Proteins 0.000 description 21
- 238000009396 hybridization Methods 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 210000001842 enterocyte Anatomy 0.000 description 19
- 230000004807 localization Effects 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 19
- 230000000295 complement effect Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 15
- 102000035195 Peptidases Human genes 0.000 description 13
- 108091005804 Peptidases Proteins 0.000 description 13
- 230000008045 co-localization Effects 0.000 description 13
- 210000000172 cytosol Anatomy 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 108700012359 toxins Proteins 0.000 description 13
- 210000005081 epithelial layer Anatomy 0.000 description 12
- 238000002073 fluorescence micrograph Methods 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- 229930182817 methionine Natural products 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 210000002175 goblet cell Anatomy 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 9
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 9
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 9
- 238000010820 immunofluorescence microscopy Methods 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 102000007079 Peptide Fragments Human genes 0.000 description 8
- 108010033276 Peptide Fragments Proteins 0.000 description 8
- 238000005286 illumination Methods 0.000 description 8
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 235000019833 protease Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 108091016585 CD44 antigen Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 7
- 229920002971 Heparan sulfate Polymers 0.000 description 7
- 108090000054 Syndecan-2 Proteins 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 150000001945 cysteines Chemical group 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 210000004347 intestinal mucosa Anatomy 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000005730 ADP ribosylation Effects 0.000 description 5
- 108010077805 Bacterial Proteins Proteins 0.000 description 5
- 102100031334 Elongation factor 2 Human genes 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 241000723792 Tobacco etch virus Species 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 231100000654 protein toxin Toxicity 0.000 description 5
- 210000003660 reticulum Anatomy 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101001072067 Homo sapiens Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108090000787 Subtilisin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 210000001163 endosome Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 229940076144 interleukin-10 Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108030001720 Bontoxilysin Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 108010049048 Cholera Toxin Proteins 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 101710146739 Enterotoxin Proteins 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000270322 Lepidosauria Species 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 102100036371 Proprotein convertase subtilisin/kexin type 4 Human genes 0.000 description 3
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 3
- 108010079723 Shiga Toxin Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 229940053031 botulinum toxin Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000147 enterotoxin Substances 0.000 description 3
- 231100000655 enterotoxin Toxicity 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000004955 epithelial membrane Anatomy 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 239000002096 quantum dot Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000007723 transport mechanism Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229960005356 urokinase Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010056891 Calnexin Proteins 0.000 description 2
- 102000034342 Calnexin Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 108090000426 Caspase-1 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 2
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 2
- 208000036756 Diphtheria carrier Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100041033 Golgin subfamily B member 1 Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 2
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 2
- 108090000545 Proprotein Convertase 2 Proteins 0.000 description 2
- 102000004088 Proprotein Convertase 2 Human genes 0.000 description 2
- 108090000544 Proprotein convertase 1 Proteins 0.000 description 2
- 102000004085 Proprotein convertase 1 Human genes 0.000 description 2
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000948099 Solenopsis invicta Chymotrypsin-1 Proteins 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 210000004082 barrier epithelial cell Anatomy 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000004890 epithelial barrier function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000008978 intestinal localization Effects 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 108010053687 macrogolgin Proteins 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 102000014452 scavenger receptors Human genes 0.000 description 2
- 108010078070 scavenger receptors Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 210000003412 trans-golgi network Anatomy 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000028973 vesicle-mediated transport Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KCCDSHMVQWPFBC-QQUOXUDESA-N (2s,3s)-2-[[(2s)-2-[[(2s)-3-(4-hydroxyphenyl)-2-[[(2s)-3-methyl-2-[[(2s)-3-phenyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoyl]amino]butanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1NCCC1)C(C)C)C1=CC=C(O)C=C1 KCCDSHMVQWPFBC-QQUOXUDESA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WUPHOULIZUERAE-UHFFFAOYSA-N 3-(oxolan-2-yl)propanoic acid Chemical compound OC(=O)CCC1CCCO1 WUPHOULIZUERAE-UHFFFAOYSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 241000726096 Aratinga Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- AEZCCDMZZJOGII-DCAQKATOSA-N Asn-Met-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O AEZCCDMZZJOGII-DCAQKATOSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710151712 Basement membrane-specific heparan sulfate proteoglycan core protein Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241001060848 Carapidae Species 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001463014 Chazara briseis Species 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 101710164760 Chlorotoxin Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- NAPULYCVEVVFRB-HEIBUPTGSA-N Cys-Thr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CS NAPULYCVEVVFRB-HEIBUPTGSA-N 0.000 description 1
- KIMNIYLAEQGPTG-ULPCFHQZSA-N DASKALRSSGMP Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(=O)N1CCC[C@H]1C(O)=O KIMNIYLAEQGPTG-ULPCFHQZSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- AMJFNKKPHDWUAI-OWUIDHLFSA-N FPAWFTKLYPRT Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccccc1)C(C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)O)C(O)=O AMJFNKKPHDWUAI-OWUIDHLFSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- QYKBTDOAMKORGL-FXQIFTODSA-N Gln-Gln-Asp Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N QYKBTDOAMKORGL-FXQIFTODSA-N 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010064766 Glutamate formimidoyltransferase Proteins 0.000 description 1
- 102000015436 Glutamate formimidoyltransferase Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 101710119392 Hemicalcin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001069607 Homo sapiens Probable G-protein coupled receptor 75 Proteins 0.000 description 1
- 101000779672 Homo sapiens Probable inactive allantoicase Proteins 0.000 description 1
- 101000837849 Homo sapiens Trans-Golgi network integral membrane protein 2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- JVNFULBJTMEXGY-AEZLTPMFSA-N IPQVWRDWFKLP Chemical compound CCC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O JVNFULBJTMEXGY-AEZLTPMFSA-N 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- DBSLVQBXKVKDKJ-BJDJZHNGSA-N Leu-Ile-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DBSLVQBXKVKDKJ-BJDJZHNGSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710151833 Movement protein TGBp3 Proteins 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710158642 Opicalcin-1 Proteins 0.000 description 1
- 101710158651 Opicalcin-2 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100033860 Probable G-protein coupled receptor 75 Human genes 0.000 description 1
- 102100033794 Probable inactive allantoicase Human genes 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 1
- 101000955367 Pseudomonas putida Transcriptional regulatory protein XylR Proteins 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- POWNYOIZNYJOKK-TWGMSMPLSA-N QINTAKWWKTHF Chemical compound CCC(C)[C@H](NC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O POWNYOIZNYJOKK-TWGMSMPLSA-N 0.000 description 1
- 101150030875 RAB7A gene Proteins 0.000 description 1
- 101710138468 Ras-related protein Rab-1 Proteins 0.000 description 1
- 101710138480 Ras-related protein Rab7 Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101000910357 Scorpio palmatus Maurocalcin Proteins 0.000 description 1
- KZPRPBLHYMZIMH-MXAVVETBSA-N Ser-Phe-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KZPRPBLHYMZIMH-MXAVVETBSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 241000239292 Theraphosidae Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 102100028621 Trans-Golgi network integral membrane protein 2 Human genes 0.000 description 1
- LWFWZRANSFAJDR-JSGCOSHPSA-N Trp-Val Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 LWFWZRANSFAJDR-JSGCOSHPSA-N 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- ZYKYLICTRPPEAR-YNVYRQEYSA-N VSWKTWFPNLAV Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@@H](N)C(C)C)C(C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O ZYKYLICTRPPEAR-YNVYRQEYSA-N 0.000 description 1
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 241000936820 Vibrio cholerae non-O1 Species 0.000 description 1
- JNNGSZMLUKSLCX-NTFSKXSTSA-N YSPFHKWFPSMH Chemical compound CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O JNNGSZMLUKSLCX-NTFSKXSTSA-N 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052980 cadmium sulfide Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 description 1
- 229960005534 chlorotoxin Drugs 0.000 description 1
- 210000002806 clathrin-coated vesicle Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229910052981 lead sulfide Inorganic materials 0.000 description 1
- 229940056932 lead sulfide Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 108010026382 trypsin inhibitor MCoTI-II Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des constructions d'administration non naturelles isolées comprenant une construction d'administration dérivée d'une toxine bactérienne couplée à un cargo thérapeutique biologiquement actif; la construction d'administration étant apte à administrer le cargo biologiquement actif par le biais d'un transport de transcytose à travers une cellule épithéliale; et la construction d'administration ne comprenant pas de domaine de translocation dérivé de toxine bactérienne ou de domaine catalytique dérivé de toxine bactérienne (cytotoxique).
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640188P | 2018-03-08 | 2018-03-08 | |
| US201862640168P | 2018-03-08 | 2018-03-08 | |
| US201862640194P | 2018-03-08 | 2018-03-08 | |
| US62/640,188 | 2018-03-08 | ||
| US62/640,194 | 2018-03-08 | ||
| US62/640,168 | 2018-03-08 | ||
| US62/756,889 | 2018-11-07 | ||
| PCT/US2019/021474 WO2019173787A1 (fr) | 2018-03-08 | 2019-03-08 | Constructions d'administration dérivées de toxines pour administration orale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3093386A1 true CA3093386A1 (fr) | 2019-09-12 |
Family
ID=66102749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3093386A Pending CA3093386A1 (fr) | 2018-03-08 | 2019-03-08 | Constructions d'administration derivees de toxines pour administration orale |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU2019230230A1 (fr) |
| CA (1) | CA3093386A1 (fr) |
| PT (1) | PT3762009T (fr) |
| WO (1) | WO2019173787A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CN105541978B (zh) | 2010-09-15 | 2019-12-13 | 兰德尔·J·米斯尼 | 使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法 |
| US10624955B2 (en) | 2014-05-07 | 2020-04-21 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| EP3762009B1 (fr) * | 2018-03-08 | 2022-05-11 | Applied Molecular Transport Inc. | Constructions d'administration dérivées de toxines pour administration orale |
| CN113347997A (zh) | 2018-11-07 | 2021-09-03 | 应用分子运输公司 | 用于经口递送异源有效载荷的Cholix衍生的携带体 |
| JP2022506990A (ja) | 2018-11-07 | 2022-01-17 | アプライド モレキュラー トランスポート インコーポレイテッド | トランスサイトーシスのための送達構築物および関連する方法 |
| EP3844169A4 (fr) * | 2019-08-16 | 2021-12-15 | Applied Molecular Transport Inc. | Compositions, formulations et production et purification d'interleukines |
| WO2021155281A1 (fr) * | 2020-01-31 | 2021-08-05 | Applied Molecular Transport Inc. | Compositions et méthodes pour le traitement de la maladie cœliaque |
| TW202245842A (zh) * | 2021-02-16 | 2022-12-01 | 美商應用分子運輸公司 | 具鋅之固體口服組合物 |
| WO2022240407A1 (fr) * | 2021-05-12 | 2022-11-17 | Applied Molecular Transport Inc. | Constructions d'administration dérivées de toxines bactériennes et utilisations associées |
| WO2022241167A1 (fr) * | 2021-05-12 | 2022-11-17 | Applied Molecular Transport Inc. | Constructions d'administration dérivées de toxines bactériennes et utilisations associées |
| WO2023141527A1 (fr) * | 2022-01-21 | 2023-07-27 | Applied Molecular Transport Inc. | Constructions d'administration clivables par furine |
| WO2023196532A1 (fr) * | 2022-04-08 | 2023-10-12 | Applied Molecular Transport Inc. | Constructions d'il-10/vecteur chimériques pour le traitement de la pochite et procédés d'utilisation |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| DE3377484D1 (en) | 1982-04-19 | 1988-09-01 | Nissan Motor | Method for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| US5272065A (en) | 1983-10-20 | 1993-12-21 | Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5807832A (en) | 1987-06-09 | 1998-09-15 | Biotech Australia Pty Limited | Oral delivery of biologically active substances bound to vitamin B12 |
| US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| ES2109362T3 (es) | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
| US6613332B1 (en) | 1991-06-21 | 2003-09-02 | The University Of Cincinnati | Oral administration of therapeutic proteins |
| EP0682524B1 (fr) | 1993-02-02 | 2001-10-04 | XOMA Technology Ltd. | Compositions pharmaceutiques contenant une proteine bactericide accroissant la permeabilite, ainsi qu'un agent tensioactif |
| GB9320782D0 (en) | 1993-10-08 | 1993-12-01 | Univ Leeds Innovations Ltd | Stabilising of proteins on solution |
| GB9420355D0 (en) | 1994-10-10 | 1994-11-23 | Univ Nottingham | Preparation of protein microspheres, films and coatings |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
| WO1999006429A1 (fr) | 1997-08-01 | 1999-02-11 | Toray Industries, Inc. | Stabilisation de proteines utiles et compositions a base de proteines utiles |
| US6342611B1 (en) | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
| US6592847B1 (en) | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
| EP1220682B1 (fr) | 1999-10-04 | 2006-11-22 | Novartis Vaccines and Diagnostics, Inc. | Compositions pharmaceutiques liquides stabilisees contenant un polypeptide |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
| CN105541978B (zh) * | 2010-09-15 | 2019-12-13 | 兰德尔·J·米斯尼 | 使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法 |
| US8877161B2 (en) | 2011-10-19 | 2014-11-04 | Georgia Regents Research Institute, Inc. | GM1-like peptides and uses thereof |
| US10624955B2 (en) * | 2014-05-07 | 2020-04-21 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
-
2019
- 2019-03-08 PT PT197170137T patent/PT3762009T/pt unknown
- 2019-03-08 CA CA3093386A patent/CA3093386A1/fr active Pending
- 2019-03-08 WO PCT/US2019/021474 patent/WO2019173787A1/fr unknown
- 2019-03-08 AU AU2019230230A patent/AU2019230230A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3762009T (pt) | 2022-08-22 |
| WO2019173787A8 (fr) | 2021-07-01 |
| AU2019230230A1 (en) | 2020-10-22 |
| WO2019173787A1 (fr) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3093386A1 (fr) | Constructions d'administration derivees de toxines pour administration orale | |
| US11426466B2 (en) | Toxin-derived delivery constructs for pulmonary delivery | |
| US10799565B2 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| US7713737B2 (en) | Methods and compositions for needleless delivery of macromolecules | |
| US10617741B2 (en) | Compositions and methods for oral delivery of therapeutic cargo | |
| KR102057356B1 (ko) | Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법 | |
| IL282986B2 (en) | Colics-derivative carriers for oral administration of heterologous cargo | |
| CN103140236A (zh) | 生长激素多肽及其制备和使用方法 | |
| EA017690B1 (ru) | Мутанты fgf21 и их применение | |
| US20220275029A1 (en) | Compositions and particles for payload delivery | |
| US20210220446A1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| WO2022240407A1 (fr) | Constructions d'administration dérivées de toxines bactériennes et utilisations associées |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240308 |